' Paradigm Shift': Luspatercept for MDS'Paradigm Shift': Luspatercept for MDS
Luspatercept showed significant improvement over erythropoiesis-stimulating agent epoetin alfa in reducing dependency on red blood cell transfusions in patients with LR-MDS who are ESA naive.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 1, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Horse Doping Drug Supplier Sentenced to 11 Years in Prison
FDA OCI, Seth Fishman, DVM, sentence, Equestology, 11 years, prison, scheme, untestable, performance enhancing, drugs, PEDs, horseracing, scheme, manufacture, distribute, receive, adulterated, misbranded, unsafe, untested, mislead, lie, authorities, BB3, Epogen-mimetic, VO2Maz, bleeder pills, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - July 12, 2022 Category: Medical Law Authors: DOJ Source Type: news
Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” said Alex Gorsky, C...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Roxadustat Noninferior to Epoetin Alfa in Dialysis Patients
FRIDAY, July 26, 2019 -- Roxadustat is noninferior to epoetin alfa for increasing hemoglobin levels among patients with anemia who are undergoing dialysis, and is superior to placebo for patients not undergoing dialysis, according to two studies... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2019 Category: Pharmaceuticals Source Type: news
epoetin alfa, Epogen, Procrit
Title: epoetin alfa, Epogen, ProcritCategory: MedicationsCreated: 9/19/2000 12:00:00 AMLast Editorial Review: 7/8/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 8, 2019 Category: Drugs & Pharmacology Source Type: news
Retacrit (Epoetin Alfa-epbx Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2019 Category: Drugs & Pharmacology Source Type: news
Retacrit (Epoetin Alfa-epbx Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 4, 2018 Category: Drugs & Pharmacology Source Type: news
First Epoetin Alfa Biosimilar Approved in the US First Epoetin Alfa Biosimilar Approved in the US
The first biosimilar erythropoiesis-stimulating agent has received FDA approval for a number of indications. It is expected to be less costly than the patented biologic.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the Treatment of Anemia
May 15, 2018 -- The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Approves'Biosimilar' Drug to Treat Certain Types of Anemia
TUESDAY, May 15, 2018 -- Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first " biosimilar " to the anemia drugs Epogen and Procrit.
Epogen and Procrit are approved to treat anemia caused by chronic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 15, 2018 Category: Pharmaceuticals Source Type: news
FDA approves first epoetin alfa biosimilar for the treatment of anemia
FDA approves Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 15, 2018 Category: American Health Source Type: news
' BioSimilar' Drug Retacrit (Epoetin Alfa-epbx) Approved to Treat Certain Types of Anemia
TUESDAY, May 15, 2018 -- Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first " biosimilar " to the anemia drugs Epogen and Procrit.
A biosimilar, derived from a living organism, has been proven to be... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 15, 2018 Category: General Medicine Source Type: news
FDA approves first epoetin alfa biosimilar for the treatment of anemia
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. (Source: World Pharma News)
Source: World Pharma News - May 15, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen
$780 Million Payment to be Funded From Joint Venture's Existing Cash Holdings
Kyowa Hakko Kirin to Continue as Licensee in Asia
THOUSAND OAKS, Calif., Oct. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Amgen and Kirin Holdings (Kirin) have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin's shares in the joint venture and, as a result, Kirin-Amgen will become a wholly-owned subsidiary of Amgen.
Kirin-Amgen was established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the global development of EPOGEN® (epoetin alfa). Over time, the scope ...
Source: Amgen News Release - October 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
